MDMA
MindMed Starts Dosing Patients In Phase 1 Clinical Study On MDMA-Like Substances
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Tuesday that the first patient has been dosed
The post MindMed Starts Dosing…
Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced on Tuesday that the first patient has been dosed in a Phase 1 investigator-initiated study aimed to evaluate the effects of MDMA-like substances. The study is being led by the firm’s collaborator and the program’s principal investigator, Dr. Matthias Liechti at University Hospital Basel.
The trial involves 24 healthy subjects who will randomly receive doses of MDMA or MDMA-like substances like MDA, Lys-MDMA, and Lys-MDA, while the rest will get placebo treatments. The study aims to assess the subjective effects of the various drugs for future application of the substance in treating disorders.
“By using pharmacokinetics and modern psychological and psychometric tests, this study will investigate the potential to better control the bioavailability, slow the effect onset and reduce possible adverse effects of MDMA and MDA by using these prodrugs,” said Dr. Liechti.
The principal investigator also said the study will investigate the “effects of MDA in direct comparison with MDMA for the first time in humans.”
Executive President Dr. Miri Halperin Wernli added that the study “will enhance our understanding of the therapeutic properties involved in the induction of positive mood in a way that may help optimize the treatment model for our R(-)-MDMA drug candidate.”
The firm started in October 2021 to develop R(-)-MDMA for treating symptoms related to autism spectrum disorder.
Mind Medicine Inc. last traded at $9.35 on the NEO.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
The post MindMed Starts Dosing Patients In Phase 1 Clinical Study On MDMA-Like Substances appeared first on the deep dive.
mdma mind medicine mindmed research-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics7 days ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week ago
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin3 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush